Immunotherapy Against Lung Cancer
Emerging Opportunities and Challenges
(Sprache: Englisch)
This book provides insight into the various immunotherapeutic approaches for the treatment of lung cancers. The chapters of the book discuss the detailed mechanisms of checkpoint inhibitors, co-stimulatory molecules, drugs working in the immunosuppressive...
Jetzt vorbestellen
versandkostenfrei
Buch (Gebunden)
Fr. 212.50
inkl. MwSt.
- Kreditkarte, Paypal, Rechnungskauf
- 30 Tage Widerrufsrecht
Produktdetails
Produktinformationen zu „Immunotherapy Against Lung Cancer “
Klappentext zu „Immunotherapy Against Lung Cancer “
This book provides insight into the various immunotherapeutic approaches for the treatment of lung cancers. The chapters of the book discuss the detailed mechanisms of checkpoint inhibitors, co-stimulatory molecules, drugs working in the immunosuppressive environment, and various vaccines for lung cancer. A chapter of the book explores the recent applications of the oncolytic virus in lung cancer treatment and discusses the potential and direction of oncolytic virus-based therapeutic vaccines. The chapter also elucidates the current understanding of the role of Toll-Like Receptors (TLRs) in tumor progression, and the recent progress in utilizing TLR agonists as potential therapeutic agents in lung cancer treatment. Towards the end, the book reviews the applications of stereotactic body radiation therapy (SBRT) and immunotherapy for the treatment of lung cancer. This book provides useful information to a range of audiences including clinical researchers working in the field of lung cancer, and undergraduate and postgraduate students from various disciplines such as pharmacy, microbiology, immunology, pharmacology, biotechnology, and health sciences.Inhaltsverzeichnis zu „Immunotherapy Against Lung Cancer “
Chapter 1_An introduction to Lung cancer.- Chapter 2_Immunobiology of Lung cancer.- Chapter 3_Evolution of Lung cancer treatment from classical chemotherapy to advanced immunotherapy.- Chapter 4_Recent advances in the immunotherapy of Lung cancer.- Chapter 5_PD-1/PD-L1 inhibitors for the treatment of Lung cancer.- Chapter 6_CTLA-4 inhibitors for the treatment of Lung cancer.- Chapter 7_Adoptive T cell therapy for the treatment of Lung cancer.- Chapter 8_LAG-3 inhibitors for the treatment of Lung cancer.- Chapter 9_IDO and TGF-beta inhibitors for the treatment of Lung cancer.- Chapter 10_OX40 and CD40 agonists for the treatment of Lung cancer.- Chapter 11_ICOS and GITR agonists for the treatment of Lung cancer.- Chapter 12_Vaccines and oncolytic virus for the treatment of Lung cancer.-Chapter 13_Targeting Toll-like receptors for the treatment of Lung cancer.- Chapter 14_Current and future perspectives of combining chemotherapy and stereotactic body radiation therapy with immunotherapy.- Chapter 15_Synergistic potential of PD-1/PD-L1 inhibitors and CTLA-4 inhibitors for the treatment of Lung cancer.- Chapter 16_Synergistic potential of antigen-specific vaccines and immunomodulatory agents for the treatment of Lung cancer.- Chapter 17_Important biomarkers for better evaluation of checkpoint inhibitors and another immunotherapy in Lung cancer.- Chapter 18_Insight on the clinical trials of immunotherapy for the treatment of Lung cancer.- Chapter 19_Future perspectives of the Cancer Immunotherapy for the treatment of Lung cancer.Autoren-Porträt
Dr. Shvetank Bhatt is currently working as an Associate Professor in School of Health Sciences and Technology, Dr. Vishwanath Karad MIT World Peace University, Pune, Maharashtra, India. He has done M.Pharm in Pharmacology from Manipal College of Pharmaceutical Sciences, MAHE, Manipal, Karnataka and Ph.D. in Neuropharmacology from Birla Institute of Technology & Science (BITS) Pilani, Pilani Campus, Rajasthan. He has total 16 years of industrial and academic research experience. His area of specialization is CNS disorders, pain, inflammation and immunooncology. He is recipient of Prof. Duggirala Visweswaram & Prof. Sreemantalu Satyanarayana Award (Best Paper in Pharmacology-IJPER) in 2012 and 2014. He has published more than 90 papers in various journals of national and international repute. He has also published two books with Springer. He is life member of Association of Pharmaceutical Teachers of India (APTI) and Indian Pharmacological Society (IPS).ProfessorRajaraman Eri is the Associate Dean at the School of Science at RMIT University in Melbourne. Prof Eri is a veterinarian turned biomedical scientist who specializes in research investigations into colorectal cancer, functional foods (dietary fibre),clinical nutrition and gut health. Raj was awarded a master's degree in Veterinary Medicine (TN Veterinary and Animal Sciences University, India) followed by his PhD from the University of Queensland in molecular and cell biology in 2001. His subsequent postdoctoral training USA included research work mainly investigating both innate and adaptive immune responses and associated aspects of clinical translation. Between 2006 and 2010, Dr. Raj joined UQ-Mater Medical research Institute, Brisbane as a senior research officer where he was involved in ground-breaking work illustrating the role of endoplasmic reticulum stress in the pathogenesis of bowel diseases. In late 2010, he joined UTAS as an independent investigator developing a
... mehr
research laboratory dedicated to gut health, establishing an international reputation in this area over a decade. On the teaching side, he coordinates and teaches in the fields of biosciences, immunology, nutrition, and biochemistry. Dr. Raj has won multiple teaching awards including the Australian national citation for excellence in teaching in 2017.
Dr Goh Bey Hing is a full-time professor of biochemistry at Sunway University (Malaysia) and leads the Sunway Biofunctional Molecules Discovery Centre (SBMD). His research focuses on the functionality of natural products from herbs, microbes, and algae. With over 200 scientific articles, books, and patents, he has over 8000 citations and an H-index of 51. Goh provides professional advice to biotech, aquaculture, and wellness companies, and excels in education - receiving awards for teaching innovation. Goh's contributions to research, education, and community, together with his dedication to biology, earned him recognition asa Top 10 Outstanding Young Malaysian in 2020 and placed him as the first Malaysian on the Advisory Board of the International Natural Product Sciences Taskforce.
Prof Terezinha de Jesus Andreoli Pinto is based as a full Professor at the School of Pharmaceutical Sciences, University of Sao Paulo. Professor Terezinha holds more than 40 years of sound experience in academia and researches on parenteral (formulation, analytical, microbiological, and performance methods) and medical devices. Professor Terezinha authored 180 articles in scientific journals, more than 12 book chapters and also holds two patents. Alongside her career, Professor Terezinha took on management roles in the University, such as being dean of School of Pharmacy for two mandates (2004-2008 and 2012-2016) and also being chair of Deliberative Board of FURP--a pharmaceutical firm that manufactures products from the WHO Essential Medicines list, run by Sao Paulo State Government. Strong scientific skills allied
Dr Goh Bey Hing is a full-time professor of biochemistry at Sunway University (Malaysia) and leads the Sunway Biofunctional Molecules Discovery Centre (SBMD). His research focuses on the functionality of natural products from herbs, microbes, and algae. With over 200 scientific articles, books, and patents, he has over 8000 citations and an H-index of 51. Goh provides professional advice to biotech, aquaculture, and wellness companies, and excels in education - receiving awards for teaching innovation. Goh's contributions to research, education, and community, together with his dedication to biology, earned him recognition asa Top 10 Outstanding Young Malaysian in 2020 and placed him as the first Malaysian on the Advisory Board of the International Natural Product Sciences Taskforce.
Prof Terezinha de Jesus Andreoli Pinto is based as a full Professor at the School of Pharmaceutical Sciences, University of Sao Paulo. Professor Terezinha holds more than 40 years of sound experience in academia and researches on parenteral (formulation, analytical, microbiological, and performance methods) and medical devices. Professor Terezinha authored 180 articles in scientific journals, more than 12 book chapters and also holds two patents. Alongside her career, Professor Terezinha took on management roles in the University, such as being dean of School of Pharmacy for two mandates (2004-2008 and 2012-2016) and also being chair of Deliberative Board of FURP--a pharmaceutical firm that manufactures products from the WHO Essential Medicines list, run by Sao Paulo State Government. Strong scientific skills allied
... weniger
Bibliographische Angaben
- 2024, 2023, XIV, 389 Seiten, Masse: 15,5 x 23,5 cm, Gebunden, Englisch
- Herausgegeben: Shvetank Bhatt, Rajaraman Eri Eri, Bey-Hing Goh, Keshav Raj Paudel, Terezinha de Jesus Andreoli Pinto, Kamal Dua
- Verlag: Springer, Berlin
- ISBN-10: 9819971403
- ISBN-13: 9789819971404
Sprache:
Englisch
Kommentar zu "Immunotherapy Against Lung Cancer"
0 Gebrauchte Artikel zu „Immunotherapy Against Lung Cancer“
| Zustand | Preis | Porto | Zahlung | Verkäufer | Rating |
|---|
Schreiben Sie einen Kommentar zu "Immunotherapy Against Lung Cancer".
Kommentar verfassen